Some biopharma companies have been running perfusion bioreactors in a continuous mode for several decades. The choice of whether to use continuous or not was dictated by the product, and little has been published on the economics of continuous perfusion processes. In today’s blog we
Over the next couple of blogs, we’d like to take a closer look at continuous processing, including the challenges associated with it, focusing on the cost drivers for perfusion versus fed batch, and the potential for continuous downstream processing. Continuous processing has increasingly been seen
Leading university installs Biopharm’s process modelling software on 50 systems in newly opened technology centre Biopharm, the bioprocess analysis software developer, today announced that its BioSolve Process software tool has been installed on 50 workstations in the new Design Suite in the Department of Biochemical
Software demonstrates how shift from stainless steel to continuous processing technology potentially reduces CAPEX by over 75% and CoG below $20g/L Biopharm, the bioprocess analysis software developer, today announced the introduction of BioSolve Process 5, the latest version of the company’s flagship software tool. The
In conjunction with today’s launch of BioSolve Process 5, we have developed a whitepaper that demonstrates the significant savings that can be achieved by biopharma innovators in monoclonal antibody manufacture. The study used BioSolve Process to evaluate three different development scenarios: Current stainless steel technology
Biopharm is set to present a session entitled Assessing Innovation Across the Enterprise at this IChemE event on May 15, 2014. See www.techtransfer.co.uk for more info.
This week, Biopharm is chairing a panel on “Continuous Processing and Closed Cystems” at the 2014 BioProcess International Europe Summit in Prague. The summit reflects on the critical challenges facing the production, analysis and formulation of biologics. This meeting congregates top industry speakers in 5
This week, Biopharm is delivering a presentation at PDA Europe’s Modern Biopharmaceutical Manufacturing conference in Lyon, France. The presentation is entitled “Continuous Manufacturing, an Overview. Cost Drivers, Facility Impact, Quality Implications.” With a focus on the regulatory and quality aspects of biopharmaceutical production, this annual
This week, Biopharm is hosting a roundtable at Cell Culture World Congress, in Munich, Germany. Cell Culture World Congress is where all major existing and emerging players obtain practical and technical outcomes to upstream and scale-up. For more information, click here.
This week, Biopharm will be attending “Biopharmaceutical Innovation, a Vision for the Future” in London. The 10th Annual annual bioProcessUK Conference 2013 has become the UK’s leading technical networking meeting for professionals developing biological medicines. For more information, click here.
